Ceftaroline News and Research

RSS
Study finds increasing susceptibility of Staphylococcus aureus in U.S. hospital patients

Study finds increasing susceptibility of Staphylococcus aureus in U.S. hospital patients

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Overview of chlamydia trachomatis infections

Overview of chlamydia trachomatis infections

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Modern strains of MRSA have become broadly resistant to antibiotics: Study

Modern strains of MRSA have become broadly resistant to antibiotics: Study

CPT-F antibiotic drug may hold promise for treating potentially fatal MRSA pneumonia

CPT-F antibiotic drug may hold promise for treating potentially fatal MRSA pneumonia

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Teflaro receives FDA approval for treatment of bacterial infections

Teflaro receives FDA approval for treatment of bacterial infections

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Forest Laboratories' ceftaroline fosamil receives FDA Advisory Committee approval for CABP and cSSSI

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report